The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Learn about the uses, dosage, price and more for Nucala (mepolizumab), a prescription injection that treats asthma and other conditions in adults and some children.

Nucala (3x 100mg subcutaneous injection of mepolizumab) is licensed for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Nucala is a type of medicine called a “specialty” medicine. This means that you can only get it from a specialty pharmacy, which may need to ship the medicine to you.

Nucala's approval was also bolstered by older results from the late-stage Metrex study, which pitted the drug against placebo both in COPD patients with an eosinophilic phenotype and those without.

Nucala stands out as the only approved biologic that has been specifically evaluated in patients whose eosinophilic phenotype is defined by a blood eosinophil count (BEC) threshold as low as ≥ ...

GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive pulmonary disease (COPD), a common lung ...

Nucala is approved by the FDA for five indications - severe asthma, EGPA, severe eosinophilic asthma, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps.

Nucala has been approved for use as an add-on treatment for severe eosinophilic asthma in patients aged six years and older in the EU since August 2018. About Nucala (mepolizumab) ...

GlaxoSmithKline PLC’s Nucala therapy has been approved to treat patients with severe asthma attacks in combination with other drugs, the Food and Drug Administration said Wednesday.